Dermatology of the Patient with HIV

Emergency Medicine Clinics of North America

Volumn 28, Issue 2, 2010, Pages 355-368

  Khambaty, Mariam M ^a   Hsu, Sam S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatology; Emergency medicine; HIV; Rash

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ACICLOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; DARUNAVIR; ENFUVIRTIDE; FAMCICLOVIR; FLUCONAZOLE; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LATAZANAVIR; NEVIRAPINE; PERMETHRIN; SELENIUM SULFIDE; STEROID; SULFONAMIDE; TERBINAFINE; UNCLASSIFIED DRUG; VALACICLOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AIDS PATIENT; CLINICAL TRIAL; CRYPTOCOCCOSIS; DERMATOPHYTOSIS; DRUG ERUPTION; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; EYE JAUNDICE; FOLLICULITIS; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PRURITUS; INJECTION SITE REACTION; JAUNDICE; KAPOSI SARCOMA; MACULOPAPULAR RASH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAIL PIGMENTATION; PAPULAR SKIN DISEASE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RASH; REVIEW; SCABIES; SEBORRHEIC DERMATITIS; SKIN CYST; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SUPERINFECTION; TINEA VERSICOLOR; TOXIC EPIDERMAL NECROLYSIS; TOXOPLASMOSIS; AIDS RELATED COMPLEX; CHICKENPOX; DERMATOMYCOSIS; DIFFERENTIAL DIAGNOSIS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; RISK FACTOR;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CHICKENPOX; CRYPTOCOCCOSIS; DERMATITIS, SEBORRHEIC; DERMATOMYCOSES; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; FOLLICULITIS; HERPES SIMPLEX; HISTOPLASMOSIS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PSORIASIS; RISK FACTORS; SARCOMA, KAPOSI; SCABIES; STEVENS-JOHNSON SYNDROME;

EID: 77952481558     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2010.01.001     Document Type: Review

References (34)

1. Coopman S.A., Johnson R.A., Platt R., et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993, 328:1670-1674.
2. Weismann K., Petersen C.S., Sondergaard J., et al. Skin signs in AIDS: textbook of AIDS/HIV infection-related dermatology 1998, Munksgaard, Copenhagen (Denmark).
3. Brehmer-Anderson E., Torssander J. The exanthema of acute (primary) HIV infection: identification of a characteristic histopathologic picture?. Acta Derm Venereol 1990, 70:85-87.
4. Hulsebosch H.J., Claessen F.A., VanGinkel C.J., et al. Human immunodeficiency virus examthen. J Am Acad Dermatol 1990, 23:483-486.
5. Abrams D.I. Clinical manifestations of HIV infection, including persistent generalized lymphadenopathy and AIDS-related complex. J Am Acad Dermatol 1990, 22:1217-1222.
6. Severson J.L., Tyring S.K. Relation between herpes simplex viruses and human immunodeficiency infections. Arch Dermatol 1999, 135:1393-1397.
7. Goodman D.S., Teplitz E.D., Wishner A., et al. Prevalence of cutaneous disease in patient with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol 1987, 17:210-220.
8. Zalla M.J., Daniel W.P., Fransway A.F. Dermatologic manifestations of human immunodeficiency virus infection. Mayo Clin Proc 1992, 67:1089-1108.
9. Cohen P.R., Beltrani V.P., Grossman M.E. Disseminated herpes zoster in patients with human immunodeficiency virus infection. Am J Med 1988, 84:1076-1080.
10. Perronne C., Lazanas M., Leport C., et al. Varicella in patients infected with the human immunodeficiency virus. Arch Dermatol 1990, 126:1033-1036.
11. Gnann J.W. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002, 186(Suppl 1):S91-S98.
12. Gilden D.H., Wright R.R., Schneck S.A., et al. Zoster sine herpete, a clinical variant. Ann Neurol 1994, 35(5):530-533.
13. Beutner K.R., Friedman D.J., Forzpaniak C., et al. Valacyclovir compared to acyclovir for the improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents Chemother 1995, 39:1546-1553.
14. Tyring S.K., Beutner K.R., Tucker B.A., et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000, 9(9):863-869.
15. Burkhart C.N., Chang H., Gotwald L. Tinea corporis in human immunodeficiency virus-positive patient: case report and assessment of oral therapy. Int J Dermatol 2003, 42:839-843.
16. Castano-Molina C., Cockerell C.J. Diagnosis and treatment of infectious diseases in HIV-infected hosts. Dermatol Clin 1997, 15:267-283.
17. Thappa D.M., Karthikeyan K. Exaggerated scabies: a marker for HIV infection. Indian Pediatr 2002, 39:875-876.
18. Mathieu M.E., Wilson B.B. Scabies. Principles and practice of infectious diseases 2005, 3304-3307. Elsevier, Philadelphia. 6th edition. G.L. Mandell, J.E. Bennet, R. Dolin (Eds.).
19. Rzanky B., Hamouda O., Schoph E. Incidence of Stevens-Johnson syndrome, and toxic epidermal necrolysis in patients with acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993, 129:1059.
20. Saiag P., Caumes E., Chosidow O., et al. Drug-induced toxic epidermal necrolysis in patients infected with human immunodeficiency virus. J Am Acad Dermatol 1992, 26:567-574.
21. Chan H.L., Stern R.S., Arndt K.A., et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis; a population based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990, 126:43-47.
22. Brackett C.C., Singh H., Block J.H. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 2004, 24(7):856-870.
23. Anderson J.A., Adkinson N.F. Allergic reactions to drugs and biologic agents. JAMA 1987, 258:2891-2899.
24. Kong H.H., Myers S.A. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. Dermatol Ther 2005, 18:58-66.
25. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998, 20:1071-1092.
26. Warren K.J., Boxwell D.E., Kim N.Y., et al. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998, 351:567.
27. Barner A., Myers M. Nevirapine and rashes. Lancet 1998, 351:1133.
28. LeTiec C., Barrail A., Goujard C., et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005, 44(10):1035-1050.
29. Goodman D.S., Teplitz E.D., Wisher A., et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1986, 17:210-220.
30. Johnson T.M., Duvic M., Rapini R.P., et al. AIDS exacerbates psoriasis. N Engl J Med 1985, 313:1415.
31. Obuch M.L., Maurer T.A., Becker B., et al. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol 1992, 275:667-673.
32. Rigopoulos J., Paparizos V., Katsambas A. Cutaneous markers of HIV infection. Clin Dermatol 2004, 22:487-498.
33. Eisman S. Pruritic papular eruptions of HIV-1. Dermatol Clin 2006, 24:449-457.
34. Rajendran P.M., Dolev J.C., Heaphy M.R., et al. Eosinophilic folliculitis: before and after the introduction of antiretroviral therapy. Arch Dermatol 2005, 141:1227-1231.